The aim of this study was to examine the influence of hormonal therapy (HT) on glucose metabolism in prostate cancer (PCa) patients. Fifty-two PCa patients receiving HT with gonadotropin-releasing hormone (GnRH) analogues and/or antiandrogen drugs were enrolled in this study. Both blood and urine samples were taken a few hours after breakfast before and after HT, and glucose levels in the blood and urine were measured. Elevations of blood glucose levels of 30-50, 50-100 and over 100 mg/dl after HT as compared with the levels before HT were observed in two, eight and five patients, respectively. Urine examination revealed deterioration of glucosuria in seven patients. The mean blood glucose level after HT was significantly higher than that measured before HT. The elevation of blood glucose level significantly correlated with concurrence of diabetes mellitus (DM) and higher body mass index (BMI) before HT. Deterioration of glucosuria significantly correlated with the concurrence of DM. HT for PCa patients, especially with concurrent DM or obesity, induces elevation of the blood glucose level and deterioration of glucosuria. Therefore, glucose intolerance should be considered during HT for PCa.
Introduction
The incidence of early prostate cancer (PCa) in Japan is now similar to that found in the USA as a result of prostate-specific antigen (PSA) testing. 1, 2 Hormonal therapy (HT) is currently administered to about half of the newly diagnosed PCa patients in Japan. 1 Hypogonadism due to HT is manifested by various adverse effects including hot flushes, 3 gynecomastia, metabolic abnormalities and changes of body composition. [4] [5] [6] [7] Although the changes in blood glucose levels in PCa patients receiving androgen deprivation therapy (ADT) has been reportedly associated with insulin resistance, 8, 9 to our knowledge, the frequency and background of patients complicated with glucose intolerance has never been reported. In this study, we evaluated the elevation of blood glucose levels and the deterioration of glucosuria in Japanese PCa patients receiving HT.
Materials and methods

Patients
Fifty-two Japanese men diagnosed pathologically with PCa who had blood and urine samples taken before and after HT between 1997 and 2006 at our institutions were enrolled in this study. They received HT for at least 3 months. The details of HT were as follows: maximum androgen blockade (MAB) in 46 (three with steroidal antiandrogen and 43 with non-steroidal antiandrogen), gonadotropin-releasing hormone (GnRH) analogue alone in three, antiandrogen (AA) alone in three (one steroidal and two non-steroidal). There were 15 patients with diabetes mellitus (DM); four received diet therapy only; nine received some oral hypoglycemic agents without insulin. The detailed characteristics of the patients are shown in Table 1 .
Exclusion criteria
Men were excluded from this study, if they had other malignancies, pancreatic diseases, a change of or a new prescription of oral hypoglycemic agents or insulin during the period of this study. We also employed the exclusion criteria of Basaria et al. 5 which were as follows: liver function tests or serum creatinine levels 42 times the upper limit of healthy individuals, glucocorticoid use in the previous 3 months, a history of thyroid disease, a history of any form of hypogonadism before the diagnosis of PCa and men who had undergone or were currently undergoing cytotoxic chemotherapy.
Sample collection and evaluation
Blood and urine samples were taken a few hours after breakfast, and glucose levels in these samples were measured directly. Elevation of blood glucose levels after HT was defined as more than 30 mg/dl in comparison with the level before HT, and the patients were classified into three groups according to the elevation of blood glucose levels: mild, 30-50; moderate, 50-100; severe, over 100 mg/dl. Glucosuria was evaluated by a qualitative test, and all cases that showed worsening after HT as compared with their status before HT were considered as having deterioration. Body mass index (BMI) was calculated by the following formula: (body weight (kg)/ height 2 (m 2 )) before HT.
Statistical analysis
We used commercially available computer software for statistical analysis. The mean values of the patients' age, BMI before HT and the median value of the duration of HT were used as cut-off points to divide the patients into two groups for statistical analysis. The Fisher's direct test and the Student's t-test were used to analyze the results with significance considered at Po0.05.
Results
Changes of the blood and urine glucose
Elevation of the blood glucose levels of more than 30 mg/dl after HT as compared with before HT were observed in a total of 15 patients (28.8%) as follows: mild, two patients (3.8%); moderate, eight patients (15.4%); severe, five patients (9.6%). The mean blood glucose levels before and after HT were 115.6 and 139.1 mg/dl, respectively ( Figure 1 ), and the difference was statistically significant (P ¼ 0.001). In 13 patients with concurrent DM, the mean blood glucose level after HT was 218.3 mg/dl, which was significantly higher than that before HT (147.2 mg/dl; P ¼ 0.0014). In 39 patients without concurrent DM, there was no significant difference between the mean glucose level before HT (105.0 mg/dl) and that after HT (112.7 mg/dl; P ¼ 0.1184).
On the other hand, the deterioration of glucosuria after HT was seen in 7 of 52 patients (13.5%).
Correlation between the changes of blood and urine glucose and the clinical factors
The blood glucose elevation and deterioration of glucosuria did not correlate with the patients' age, steroidal AA use, the kind of HT and duration of HT. The concurrence of DM and high BMI before HT significantly correlated with the elevation of blood glucose levels (Po0.0001 and P ¼ 0.0138, respectively). The concurrence of DM only correlated with the deterioration of glucosuria (P ¼ 0.0005). There was also a significant correlation between the elevation of blood glucose levels and the deterioration of glucosuria (P ¼ 0.0164; Tables 2 and 3 ).
Discussion
In this study, the blood glucose levels after HT for PCa were significantly higher than those before HT. This was especially so for those patients with concurrent DM had higher elevation of the blood glucose levels as compared with those without concurrent DM. Elevation of the blood glucose levels of more than 30 mg/dl after HT in comparison with before HT was observed in 15 (28.8%) patients. There are only a few case reports about hyperglycemia due to AA and/or GnRH analogue.
8,10,11
Schattner et al. 10 reported remarkable elevation of the blood glucose level from 120 to 880 mg/dl after 6-week therapy with cyproterone acetate (steroidal AA) for PCa. With regards to the GnRH analogues, Coddington et al.
11
reported that in a 26-year-old woman with endometriosis and DM, the evening blood glucose levels after leuprolide acetate were higher than those before treatment. Recently, Inaba et al. 8 reported hyperglycemia in an 81-year-old PCa patient without DM treated by leuprolide acetate for 7 months and in a 61-year-old PCa patient with DM treated by MAB (leuprolide acetate and flutamide) for 11 months. They also noticed that the correct homeostasis model assessment evaluation indices for the pancreatic b-cell function (HOMA-%b), and for insulin sensitivity (HOMA-%S) were reduced in these two patients as compared with control men. Glucose intolerance in prostate cancer K Suzuki et al Although steroidal AA medications have been thought to cause a greater elevation of blood glucose levels than the non-steroidal AA or GnRH analogues, due to the steroid frame, they did not correlate with elevation of the blood glucose levels and deterioration of glucosuria in the present study. The glucose intolerance owing to HT for PCa did not have any correlation with the kind of HT used in this study as well as in the previous reports. 8, 10, 11 With regards to the correlation between glucose intolerance after HT and the clinical factors, a significant correlation between elevation of the blood glucose levels and the concurrence of DM or BMI before HT was found. On the other hand, the deterioration of glucosuria significantly correlated with the concurrence of DM in this study. HT (ADT) for PCa causes various metabolic abnormalities. Smith et al. 4 described that after 3 months of ADT, the fat mass increased and the lean body mass decreased significantly as compared with baseline measurements, but there were no changes in the blood lipids or glucose during treatment. Alternatively, after 12 months of ADT, the bone mineral density, sexual function and QOL score decreased, 5 whereas the upper body strength, 5 body weight, 6 BMI, 7,9 total cholesterol 7 and triglyceride 7 increased significantly in addition to the changes in the fatty body mass and lean body mass. 6 With regards to glucose intolerance, after 12-month ADT, the fasting blood glucose and fasting serum insulin levels, in the homeostatic model assessment for insulin resistance (HOMA IR ) were significantly higher than those in the non-ADT or control groups. 4, 9 Mechanisms of glucose intolerance after HT for PCa have been suggested based on the previous reports as follows: (1) the increased fat mass after HT influences the insulin concentration and insulin sensitivity, 4, 8, 9 (2) testosterone has a direct effect on pancreatic islet function by favoring insulin gene expression and release, and the decrease in the testosterone level after HT reduces the pancreatic functions.
8,12
The results of this study were supported by the hypothetical mechanism of glucose intolerance in the previous reports. Our present study had some drawbacks related to the evaluation of blood glucose levels and number of patients examined. Although the blood glucose levels were evaluated a few hours after breakfast, blood samples were taken under the same conditions before and after HT. Moreover, the number of the patients was small, and further investigations on more patients are needed. Elevation of blood glucose levels after hormonal therapy was defined as more than 30 mg/dl elevation than before hormonal therapy. b Cases (7/10) were treated with oral hypoglycemic agents. **Fisher's direct test.
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In conclusion, we need to pay attention to glucose intolerance, when PCa patients, especially those with concurrent DM or obesity, are treated with HT.
